PRESTIGE CONSUMER HEALTHCARE INC.
boothcheck covers PRESTIGE CONSUMER HEALTHCARE INC. (PBH) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 28, 2026.
• Prestige owns a portfolio of niche over-the-counter consumer health brands at a 28% operating margin, the economics of category leaders that need little reinvestment and throw off steady cash. • The cash funds an acquisition machine: the company is buying the Breathe Right nasal-strip brand and Australia's LaCorium skin-care business, financed with new term debt that lifts leverage before cash flow brings it back down. • The structural worry is organic decline, full-year revenue fell about 4%,
Is PBH overvalued? See what's priced in →
341 institutional managers reported holding PBH in 13F filings for the quarter ended 2026-03-31. 47 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 2.9M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PBH has cut its share count 4.5% over the past five years, spending $305.65M on repurchases. It pays no dividend. Cash returned over the past three years: $219.59M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at PBH over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PBH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +2.1% | -13.2% |
| 2023-11-03 | +0.1% | -1.2% |
| 2024-02-09 | +9.2% | -0.6% |
| 2024-05-16 | -5.7% | +10.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PBH's latest 8-K filings: 2026-08-14 (items 5.02); 2026-08-06 (items 2.02, 7.01, 9.01); 2026-07-15 (items 1.01, 2.03, 9.01); 2026-07-06 (items 1.01, 2.03, 7.01, 9.01); 2026-06-16 (items 1.01, 2.01, 2.03, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.